Table 3.
Treatment characteristics and survival outcomes in patients with DCIS who underwent SLNDa
| ENTIRE COHORT | Negative SLN (n=1102) |
Positive SLN findings (n=432) |
P valuec (Neg vs pos SLN) |
P valued (ITCs vs mets) |
|
|---|---|---|---|---|---|
| ITCs (n=66) |
Metastasesb (n=66) |
||||
| Adjuvant chemotherapy e | 60 (5.4) | 7 (11) | 47 (71) | <.001 | <.001 |
| Adjuvant hormonal therapy | 357 (32.4) | 23 (35) | 41 (62) | <.001 | .002 |
| Adjuvant radiation therapy | 228 (20.7) | 11 (17) | 12 (18) | .363 | .819 |
| Boost to nodal basins | 0 (0.0) | 2 (3) | 4 (6) | <.001 | .440 |
| Completion ALND | ~ | 6 (9) | 45 (68) | ~ | <.001 |
| Positive node on ALND | ~ | 0 (0) | 8 (18) | ~ | .572 |
| 5-year disease-free survival | 99.3% | 100.0% | 90.9% | <.001 | .014 |
| 5-year overall survival | 96.7% | 93.9% | 89.2% | .014 | .383 |
|
| |||||
| PURE DCIS | Negative SLN (n=851) |
Positive SLN findings (n=56) |
P valuec (Neg vs pos SLN) |
P valued (ITCs vs mets) |
|
| ITCs (n=44) |
Metastasesb (n=12) |
||||
|
| |||||
| Adjuvant chemotherapy e | 3 (0.4) | 1 (2) | 6 (50) | <.001 | <.001 |
| Adjuvant hormonal therapy | 217 (25.5) | 11 (25) | 8 (67) | .172 | .015 |
| Adjuvant radiation therapy | 158 (18.6) | 5 (11) | 0 (0) | .067 | .574 |
| Boost to nodal basins | 0 (0.0) | 0 (0) | 0 (0) | * | * |
| Completion ALND | ~ | 1 (2) | 3 (25) | ~ | .028 |
| Positive node on ALND | ~ | 0 (0) | 0 (0) | ~ | * |
| 5-year disease-free survival | 99.7% | 100.0% | 100.0% | .679 | * |
| 5-year overall survival | 96.8% | 96.9% | 90.9% | .637 | .342 |
|
| |||||
| OCCULT INVASION | Negative SLN (n=251) |
Positive SLN findings (n=76) |
P valuec (Neg vs pos SLN) |
P valued (ITCs vs mets) |
|
| ITCs (n=22) |
Metastasesb (n=54) |
||||
|
| |||||
| Adjuvant chemotherapy e | 57 (22.7) | 6 (27) | 41 (76) | <.001 | <.001 |
| Adjuvant hormonal therapy | 140 (55.8) | 12 (55) | 33 (61) | .540 | .534 |
| Adjuvant radiation therapy | 70 (27.9) | 6 (27) | 12 (22) | .447 | .639 |
| Boost to nodal basins | 0 (0.0) | 2 (9) | 4 (7) | <.001 | 1.000 |
| Completion ALND | ~ | 5 (23) | 42 (78) | ~ | <.001 |
| Positive node on ALND | ~ | 0 (0) | 8 (19) | ~ | .571 |
| 5-year disease-free survival | 97.9% | 100.0% | 88.8% | .008 | .129 |
| 5-year overall survival | 96.4% | 87.9% | 88.8% | .026 | .876 |
ALND, axillary lymph node dissection; DCIS, ductal carcinoma in situ; ITCs, isolated tumor cells; mets, metastases; SLN, sentinel lymph node.
Values in table are number of patients (percentage) unless otherwise indicated.
Metastases includes micrometastases and macrometastases.
Comparison between negative SLN group versus positive SLN group.
Comparison within positive SLN group (isolated tumor cells versus SLN metastases).
Patients who received adjuvant chemotherapy for a concurrent other cancer were included in the analysis (n=3 in the pure DCIS, negative SLN group; n=1 in the occult invasion, negative SLN group).
Unable to compute statistics because groups are exactly equivalent.